Infect Dis Ther May 2023 PMID 37185797

Safety, Pharmacokinetics, Serum Neutralizing Titers, and Immunogenicity of Adintrevimab, a Monoclonal Antibody Targeting SARS-CoV-2: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Dose-escalation Study in Healthy Adults.

Pete Schmidt, Jean Gong, Kristin Narayan, Deepali Gupta, Frank Engler, Yong Li, Amanda Copans, Ed Campanaro

Download social card

Mentions

Peak: 1 in Sep 2023

across 2 sources since Sep 2023

Extended reach

1,457

potential audience

Total likes

Video views

Mentions per month

Sep 2023 – Mar 2024

Where it's discussed

X / Twitter1 posts
YouTube1 videos

AI synopsis

What people are saying

The discussion emphasizes future research directions with mentions of the Omicron variant and vaccinated versus non-vaccinated populations, suggesting a moderate level of interest but limited depth in analysis, reflected in phrases like 'non vaccinés' and 'si on veut espérer', which are speculative rather than analytical.

AgreementNeither agree nor disagree

The discussion raises a hypothetical scenario about Omicron populations and vaccine outcomes, but does not clearly agree or disagree with the publication's findings.

InterestModerate interest

The discussion shows some interest, primarily through referencing specific variants (Omicron) and vaccination, indicating engagement with the topic.

EngagementNeutral engagement

The post reflects minimal engagement, mostly expressing a potential future scenario without detailed analysis or back-and-forth.

ImpactNeutral impact

There is limited indication that this discussion has a significant impact on the broader understanding or application of the study's findings, as it is somewhat speculative.

Abstract in brief

This phase 1 study tested adintrevimab, a fully human monoclonal antibody designed to target SARS-CoV-2 and other related viruses, by giving it to healthy adults to evaluate its safety, how the drug behaves in the body, and how well it produces neutralizing antibodies.
Participants received different doses either via intramuscular or intravenous injection, with no serious adverse events reported; most side effects were mild, involving viral infections or respiratory symptoms.
Adintrevimab showed a predictable, dose-dependent pharmacokinetic profile with an extended half-life averaging around 96-100 days, indicating it remains in the body for a long period, supporting its potential use for preventing or treating COVID-19.]

Read the full abstract

All mentions

Adintrevimab Safety and Pharmacokinetics for COVID-19 Prevention and Treatment

This phase 1 study evaluated the safety, pharmacokinetics, and immunogenicity of Adintrevimab, a monoclonal antibody targeting SARS-CoV-2. Participants received various doses via intramuscular or intravenous injection…

Social RTCL TV · Sep 16, 2023 12 views

MARY Aurélien

@MARYau_MCU_PH · X

@etienneb1 Des populations omicron 2021, non vaccinés. De la niche en 2024 si on veut espérer les mêmes résultats que les RCT. https://t.co/51w275TuPs https://t.co/AKM1CnIZPM

Mar 25, 2024 · 1,445 followers View post →